This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D76.3 | Synonyms: giant cell reticulohistiocytoma, solitary cutaneous reticulohistiocytoma, Giant cell reticulohistiocytoma, Solitary cutaneous reticulohistiocytoma
Reticulohistiocytoma is a rare histiocytic proliferative skin lesion first described by Zak in 1954. Zak first reported a characteristic aggregation of multinucleated giant cells and histiocytes with large, abundant cytoplasm in solitary skin nodules. The name 'reticulohistiocytoma' derives from the meaning of a tumor composed of histiocytes of the reticulum cell lineage.
Reticulohistiocytoma is divided into two types: the solitary (isolated) cutaneous form and the systemic form, multicentric reticulohistiocytosis (MRH). Since MRH was first reported by Weber and Freudenthal in 1937, it has been recognized as a systemic disease characterized by multiple nodules, destructive arthritis, and systemic involvement. The solitary form (ICD D76.3) refers to lesions confined to the skin without systemic involvement.
In the new classification system of the Histiocyte Society in 2016, reticulohistiocytoma and MRH were included in the 'R group (Rosai-Dorfman disease and reticulohistiocytoma-related disorders)'. As the molecular biological understanding of histiocytic disorders advances, MAPK pathway abnormalities have also been found in some reticulohistiocytomas.
The exact cause of solitary reticulohistiocytoma has not yet been fully elucidated. There is a hypothesis that the solitary cutaneous form may arise reactively at sites of trauma, local irritation, or chronic infection, but the evidence is insufficient.
About 25–30% of MRH cases are accompanied by autoimmune diseases (rheumatoid arthritis, thyroid disease, diabetes, SLE, etc.). An association with malignancy has been reported in about 25%, and a paraneoplastic mechanism has been proposed. Associations with infectious factors such as tuberculosis and viral infections have also been reported.
Abnormal activation of histiocytes and multinucleated giant cells and abnormalities of lipid metabolism are presumed to be involved in pathogenesis. The characteristic pink ground-glass appearance of the cytoplasm is understood to be due to accumulation of lipids and glycoproteins within lysosomes.
No clear familial or genetic predisposition has been reported for solitary reticulohistiocytoma. Occurrence is, as a rule, sporadic.
Somatic mutations in the MAPK pathway, such as BRAF and MAP2K1, have been reported in some cases of reticulohistiocytoma and MRH, but these are findings in a small number of cases, and the overall genetic basis has not yet been established.
Some studies of HLA associations have been conducted, but no clear HLA association has been established. There are reports that MRH occurs more often in patients with an immune background showing some autoimmune tendencies.
Reticulohistiocytoma is an extremely rare disease, with only several hundred cases reported worldwide. The multicentric form (MRH) is so rare that fewer than 300 cases have been reported in the literature worldwide.
Solitary cutaneous reticulohistiocytoma can occur at any age and occurs mainly in adults (30s to 60s). The multicentric form (MRH) occurs mainly in women in their 40s to 60s, with a female-to-male ratio of about 3:1, higher in women.
In Korea, reticulohistiocytoma and MRH are reported very rarely. There are sporadic case reports in Korean dermatology and rheumatology journals, and it is so rare that the annual number of cases is difficult to estimate.
The multinucleated giant cells characteristic of reticulohistiocytoma are recognized as deriving from cells of the mononuclear phagocyte (macrophage, monocyte) lineage. These cells express macrophage markers such as CD68 and CD163 and are presumed to form multinucleated giant cells through fusion of multiple macrophages.
The pink ground-glass appearance of the cytoplasm is due to abnormal accumulation of lipids (especially phospholipids) and glycoproteins within lysosomes. The exact mechanism of this metabolic abnormality has not been clearly elucidated, but abnormalities of lysosomal enzymes or of intracellular signal transduction are presumed to be involved.
In MRH, inflammatory cytokines such as TNF-α, IL-1β, IL-6, IL-12, and IL-17 are excessively secreted, inducing tissue infiltration by histiocytes and giant cells and joint destruction. There are study results showing that overexpression of M-CSF (CSF1) and its receptor (CSF1R) contributes to reticulohistiocyte proliferation.
Solitary reticulohistiocytoma generally presents as a single skin nodule and is often painless. The main lesion is a skin-colored to brown or pink dome-shaped papule or nodule, ranging from a few mm to a few cm in diameter. It can occur at any site, including the head, neck, extremities, and trunk. There are no systemic symptoms.
MRH is characterized by multiple skin nodules and destructive polyarthritis. Joint symptoms: symmetric polyarthritis, with frequent involvement of the interphalangeal joints of the fingers in particular, leading in severe cases to destruction of cartilage and bone (mutilating arthritis). Skin lesions: multiple papules and nodules, characteristically clustered around the fingers and around the nose ('coral bead' sign). Systemic symptoms: fever, weight loss, and fatigue may accompany.
Solitary form: a single dome-shaped papule or nodule 5–20 mm in diameter, skin-colored to pinkish-brown, with a smooth or verrucous surface. Multicentric form (MRH): numerous brown to pink papules and nodules, arranged in clusters especially around the joints of the fingers and toes and around the nose.
In MRH, swelling, tenderness, and limited range of motion of the finger joints. Radiographic findings: subchondral erosion, bone destruction (mutilating arthritis). Joint involvement may appear before skin lesions.
Skin biopsy shows a characteristic aggregation of multinucleated giant cells and mononuclear histiocytic cells. The cytoplasm is abundant and characterized by a pink ground-glass appearance. Immunohistochemistry is positive for CD68+, CD163+, HAM56+, lysozyme+ and negative for S100 and CD1a.
In patients with a combination of skin nodules and polyarthritis, reticulohistiocytoma and MRH should be included in the differential diagnosis. Particularly when multiple skin nodules are accompanied by destructive arthritis, a skin biopsy is performed early.
Because malignancy accompanies about 25% of MRH patients, malignancy screening tests such as chest X-ray, abdominal/pelvic CT, mammography, and blood tumor marker tests are performed at diagnosis.
General blood tests and erythrocyte sedimentation rate (ESR), CRP, and autoantibody (ANA, RF) tests assess the autoimmune background and the degree of systemic inflammation.
Confirmation is by histopathological diagnosis on skin biopsy. Under light microscopy, aggregates of mononuclear and multinucleated giant cells with abundant pink ground-glass cytoplasm are observed in the dermis. Immunohistochemical staining confirming CD68+, CD163+, S100-, CD1a- differentiates it from Langerhans cell histiocytosis, tuberculous granuloma, foreign body reaction, etc.
Electron microscopy shows pleomorphic granules of lysosomal origin in the cytoplasm (complex cytoplasmic inclusions), reflecting lipid and glycoprotein accumulation.
Hand radiographs and MRI to assess joint involvement: subchondral erosion, loss of joint space. Chest·abdominal CT or PET-CT to assess systemic involvement.
Solitary reticulohistiocytoma can mostly be cured by surgical excision (complete excision) alone. Recurrence is rare, and additional treatment is generally not needed after complete excision. Spontaneous resolution with observation alone has also been reported in some small lesions.
There is no standardized protocol for the treatment of MRH, but the following agents are used.
When a malignancy is found in MRH, the reticulohistiocytosis sometimes improves after treatment of the malignancy, so aggressive treatment of the accompanying malignancy is important.
Solitary cutaneous reticulohistiocytoma rarely recurs after surgical excision and has a very good prognosis. Malignant transformation has been reported very rarely.
MRH in some cases progresses over several years and eventually undergoes spontaneous remission, but if destructive arthropathy develops before that, permanent joint deformity and functional impairment remain. A life-threatening course is rare, but when there is an accompanying malignancy, it determines the prognosis.
Because the cause of solitary reticulohistiocytoma is unclear, there is no specific prevention.
Malignancy screening is performed at the diagnosis of MRH, and accompanying malignancies are detected early with regular follow-up testing thereafter. When a malignancy is found, aggressive treatment can improve the course of MRH.
In patients with MRH, it is important to minimize the progression of destructive arthritis and preserve joint function through early initiation of treatment (methotrexate, biologics). Regular joint function assessment and rehabilitation therapy are provided concurrently.